[
  {
    "ts": null,
    "headline": "Edwards secures CE mark for transfemoral mitral valve implant",
    "summary": "Edwards’ mitral valve implant approval in Europe mounts a challenge to long-time market dominator Abbott.",
    "url": "https://finnhub.io/api/news?id=caed819de1fe8e0f58b22623d60099d061322bcf7dd01e4c8896327900d53a97",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744646878,
      "headline": "Edwards secures CE mark for transfemoral mitral valve implant",
      "id": 133908627,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "EW",
      "source": "Yahoo",
      "summary": "Edwards’ mitral valve implant approval in Europe mounts a challenge to long-time market dominator Abbott.",
      "url": "https://finnhub.io/api/news?id=caed819de1fe8e0f58b22623d60099d061322bcf7dd01e4c8896327900d53a97"
    }
  },
  {
    "ts": null,
    "headline": "Edwards SAPIEN M3 Receives CE Mark, Becoming World’s First Transfemoral Transcatheter Mitral Valve Replacement System",
    "summary": "IRVINE, Calif., April 14, 2025--Edwards Lifesciences Corporation (NYSE: EW) today announced the company’s SAPIEN M3 mitral valve replacement system received CE Mark for the transcatheter treatment of patients with symptomatic (moderate-to-severe or severe) mitral regurgitation (MR) who are deemed unsuitable for surgery or transcatheter edge-to-edge (TEER) therapy. Leveraging the company’s SAPIEN technology, the SAPIEN M3 system is the world's first approved transcatheter valve replacement therap",
    "url": "https://finnhub.io/api/news?id=4f6d6d3b10e2178e5df004501e2b2740b88c03bd54d4ee6dfd30f2bacbecb99d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744632000,
      "headline": "Edwards SAPIEN M3 Receives CE Mark, Becoming World’s First Transfemoral Transcatheter Mitral Valve Replacement System",
      "id": 133908628,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "EW",
      "source": "Yahoo",
      "summary": "IRVINE, Calif., April 14, 2025--Edwards Lifesciences Corporation (NYSE: EW) today announced the company’s SAPIEN M3 mitral valve replacement system received CE Mark for the transcatheter treatment of patients with symptomatic (moderate-to-severe or severe) mitral regurgitation (MR) who are deemed unsuitable for surgery or transcatheter edge-to-edge (TEER) therapy. Leveraging the company’s SAPIEN technology, the SAPIEN M3 system is the world's first approved transcatheter valve replacement therap",
      "url": "https://finnhub.io/api/news?id=4f6d6d3b10e2178e5df004501e2b2740b88c03bd54d4ee6dfd30f2bacbecb99d"
    }
  }
]